ArticleJournal of inflammation research2024
The Role of Pentraxin 3 in the Assessment of Cardiovascular Risk and Disease Activity in Patients with Rheumatoid Arthritis and Spondyloarthritis.
Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pentraxin 3 (PTX3) is suggested to be both a marker of inflammation and cardiovascular (CV) risk. Aim: The aim of this study was to identify and compare the role of PTX3 in assessment of disease activity and CV risk, in patients with chronic inflammatory diseases, rheumatoid arthritis (RA), and spondyloarthritis (SpA). Methods: The study group consisted of 235 patients (109 RA, and 126 SpA). The following parameters were assessed: disease activity, traditional CV risk factors, carotid intima media thickness (cIMT), PTX3 plasma concentration. Results: The median (IQR) PTX3 concentration was higher in RA than SpA patients [3.44 (2.56-4.79) vs 2.51 (1.72-3.62) ng/mL, p<0.001]. The mean (SD) cIMT value was higher in RA than SpA patients [0.85 (±0.21) vs 0.75 (±0.27) mm, p=0.02]. Atherosclerotic plaques were observed in similar number of patients with RA (31, 28.4%) and SpA (34, 27%) (NS). The PTX3 level was significantly higher in RA patients with moderate/high vs low disease activity, and in patients with presence vs no atherosclerotic plagues. In patients with RA correlations were found between PTX3 and disease activity parameters: C-reactive protein, erythrocyte sedimentation rate, tender joint count, disease activity score in 28 joints, white blood cell count (WBC). In multiple linear regression analysis, significantly positive association was confirmed for PTX3 and WBC. No significant relationships were found in patients with SpA. Conclusion: The results of this study point to the dual role of PTX3 in patients with RA, as a biomarker of disease activity, and as a marker of CV complications risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.